Oxford BioMedica
Oxford Biomedica acquires ABL Europe for €15m
January 30, 2024Business Services ABL Europe, Oxford BioMedica, Pharmacy, acquisition
Oxford Biomedica has announced that it has completed the acquisition of ABL Europe from Institut Mérieux. This follows announcements on …
Oxford Biomedica joins forces with UK’s Vaccines Manufacturing and Innovation Centre to scale up production of Oxford Uni’s COVID-19 vaccine
June 8, 2020Manufacturing and Production, Sales and Marketing COVID-19, Oxford BioMedica, University of Oxford, Vaccine, coronavirus, pharma
Oxford Biomedica has forged a five-year partnership with the Vaccines Manufacturing and Innovation Centre (VMIC) to work together to provide …
Novo Holdings invests £53.5 million into Oxford Biomedica
May 30, 2019Business Services, Sales and Marketing Novo Holdings, Novo Nordisk, Oxford BioMedica, Shares, cell and gene therapy, lentivirus
Novo Holdings has agreed to buy 10.1% of shares in British firm Oxford Biomedica for £53.5 million. Novo will buy …
Oxford Biomedica to expand with fourth site, creating 100 jobs
September 13, 2018Oxford BioMedica, pharma
Gene and cell therapy group Oxford Biomedica has announced plans to expand its business with a new site located not …
Axovant attempts to rise from ashes with $842m Parkinson’s therapy deal
June 7, 2018Sales and Marketing Axovant, Oxford BioMedica, biotech, drugs, pharma, pharmaceutical
Axovant’s spectacular crash to Earth, after a soaring IPO that saw its share price hit the heady heights of $26, …
Oxford BioMedica in $100 million manufacturing deal with Novartis
July 6, 2017Manufacturing and Production, Sales and Marketing Novartis, Oxford BioMedica
Oxford BioMedica has announced that it has signed a contract with Novartis to supply the company with materials in a …
Novartis signs $90m deal with Oxford BioMedica
October 10, 2014Manufacturing and Production, Research and Development, Sales and Marketing CART-019, Novartis, Oxford BioMedica, immunotherapy, oxb
UK-based biotech Oxford BioMedica is working with Novartis in a transformational deal for the firm worth $90 million to develop …
ABPI and BIA establish new manufacturing partnership
September 23, 2014Manufacturing and Production, Sales and Marketing ABPI, Actavis, AstraZeneca, BIA, Eisai, Fujifilm Diosynth Biotechnologies, GlaxoSmithKline, Knowledge Transfer Network (KTN), Oxford BioMedica, Pfizer, Whitehead, bates, mmip
The ABPI and the Bioindustry Association (BIA) have jointly established a new Medicines Manufacturing Industry Partnership (MMIP) to boost medicines …
Oxford BioMedica takes on executive position
August 18, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Oxford BioMedica, blake
Gene and cell therapy firm Oxford BioMedica has confirmed that non-executive director Dr Paul Blake has been appointed to the …
Oxford BioMedica makes management change
February 10, 2012Research and Development, Sales and Marketing Oxford BioMedica
Gene-based biopharmaceutical firm Oxford BioMedica has announced that Andrew Wood, chief financial officer, has stepped down from the board of Oxford …
James Christie joins Oxford BioMedica as manufacturing head
February 22, 2011Manufacturing and Production James Christie, Oxford BioMedica, appointment, manufacturing and production
UK gene therapy company Oxford BioMedica has appointed James Christie as its first head of manufacturing. It following the firm’s …
Oxford BioMedica buys decommissioned facility
February 1, 2011Manufacturing and Production Oxford BioMedica, RecipharmCobra Biologics, manufacturing
Gene therapy specialist Oxford BioMedica has said it plans to acquire a £1.9 million ($3.1m) manufacturing facility from contract manufacturer …
Oxford BioMedica hopes vaccine first will raise interest
May 5, 2010Sales and Marketing Dendreon, Oxford BioMedica, Provenge, TroVax
Oxford BioMedica is hoping that the approval of the world’s first immunotherapy cancer vaccine in the US will help it …
Latest content
Five Facts about cardiovascular disease
